干扰素-α2b治疗非母婴传播HBeAg阳性慢性乙型肝炎患者疗效分析

doi:10.3969/j.issn.1672-5069.2016.04.021

Abstract

Kang Fubiao, Sun Dianxing, Li Dong, et al. Efficacy of interferon alfa-2b for treatment of patients with HBeAg positive chronic hepatitis B with non-maternal to infantile transmission[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 471-472.

References

[1] Lu FM,Zhuang H. Management of hepatitis B in China. Chin Med J （Engl）,2009,122（1）:3-4.
[2] 王建设,朱启鎔. 阻断乙型肝炎病毒母婴传播的研究进展. 中华肝脏病杂志,2002,10（4）：308-310.
[3] Caviglia GP,Abate ML,Pellicano R,et al. Chronic hepatitis B therapy:available drugs and treatment guidelines. Minerva Gastroenterol Dietol,2015,6l（2）:61-70.
[4] Tang CM,Yau TO,Yu J. Management of chronic hepatitis B infection:current treatment guidelines, challenges,and new developments.World J Gastroenterol,2014,20（20）:6262-6278.
[5] 占国清,李芳,李儒贵,等. 干扰素α-1b联合恩替卡韦治疗高病毒载量慢性乙型肝炎疗效评价. 实用肝脏病杂志,2016,19（1）：33-36.
[6] Lin FC,Young HA. Interferons: Success in anti-viral immunotherapy. Cytokine Growth Factor Rev,2014,25（4）:369-376.
[7] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[8] Lai CL,Ratziu V,Yuen MF,et al. Viral hepatitis B. Lancet, 2003,362（9401）:2089-2094.
[9] van Campenhout MJ,Janssen HL. How to achieve immune control in chronic hepatitis B. Hepatol Int,2015,9（1）:9-16.
[10] Hui CK,Leung N,Yuen ST,et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology,2007,46（2）:395-401.
[11] 庄权权,林志航,蒋燕成,等. 慢性乙型肝炎病毒感染患者血清免疫调节因子检测的临床意义. 中华医院感染学杂志,2016,26（1）：1-3.
[12] Liaw YF,Jia JD,Chan HL,et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology,2011,54（5）:1591-1599.
[13] Sonneveld MJ,Hansen BE,Piratvisuth T,et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology,2013,58（3）:872-880.
[14] EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 2012, 57（1）:167-185.
[15] 韩莹,丁惠国. 抗病毒治疗乙型肝炎肝硬化的过去、现在和将来. 实用肝脏病杂志,2015,18（5）：453-456.

Efficacy of interferon alfa-2b for treatment of patients with HBeAg positive chronic hepatitis B with non-maternal to infantile transmission

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.